Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Epilepsy
- Main trialPhase 1
- “This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy”In the company’s words, NCT07051629 on ClinicalTrials.gov
Other drugs for Epilepsy
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- PRAX-562Praxis Precision Medicines · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- EverolimusNovartis · Phase 3
Coming up1
- 15 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 15 Jan 2027 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026